Changes in Suicidality among Transgender Adolescents Following Hormone Therapy: An Extended Study.

Suicidality significantly declined from pretreatment to post-treatment among transgender and gender-diverse adolescents and young adults following hormone therapy.

• Repeated-measures ANCOVA found F(1, 426) = 34.63, P < .001, partial η² = 0.075
• Sample consisted of 432 patients at a multidisciplinary gender health clinic
• Mean follow-up duration was 679 days
• The Ask Suicide-Screening Questions (ASQ) instrument was used to measure suicidality before and after treatment initiation
• Analysis adjusted for age at treatment and treatment duration

The reduction in suicidality following hormone therapy was consistent across multiple subgroups.

• The effect was consistent across sex assigned at birth
• The effect was consistent across age at start of therapy
• The effect was consistent across treatment duration

The study used a retrospective chart review design at a multidisciplinary gender health clinic to assess within-person changes in suicidality.

• Study design was a retrospective chart review
• 432 patients were included with a mean follow-up of 679 days
• A repeated-measures ANCOVA was used to assess within-person changes over time
• The study extended prior findings with a larger sample and longer follow-up period

The authors concluded that hormone therapy is associated with clinically meaningful reductions in suicidality, providing clinical evidence supporting mental health benefits of timely access to hormone therapy.

• Authors described the reductions as 'clinically meaningful'
• Authors stated findings 'provide clinical evidence supporting the mental health benefits of timely access to HT in this population'
• The study extended prior findings with a larger sample (432 patients) and longer follow-up (mean 679 days)